Neuren Pharmaceuticals Ltd
ASX:NEU
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
12.25
25.11
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Neuren Pharmaceuticals Ltd
Neuren Pharmaceuticals Ltd
Cash from Operating Activities
Neuren Pharmaceuticals Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Cash from Operating Activities
AU$119.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
117%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Cash from Operating Activities
-AU$15.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Cash from Operating Activities
-AU$8.1m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-20%
|
|
|
Probiotec Ltd
ASX:PBP
|
Cash from Operating Activities
AU$15.7m
|
CAGR 3-Years
17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
9%
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Cash from Operating Activities
AU$11.1m
|
CAGR 3-Years
17%
|
CAGR 5-Years
39%
|
CAGR 10-Years
8%
|
|
|
Arovella Therapeutics Ltd
ASX:ALA
|
Cash from Operating Activities
-AU$6.9m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
Neuren Pharmaceuticals Ltd
Glance View
Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment and neurodegenerative disorders. The company is headquartered in Melbourne, Victoria. The company went IPO on 2005-02-03. The Company’s lead drug compound, Trofinetide, is in a Phase III clinical trial in the United States for Rett syndrome and has completed a Phase II clinical trial in Fragile X syndrome. Its both programs have each received Fast Track designation by the United States Food and Drug Administration (FDA) and Orphan Drug designation in both the United States and the European Union. The firm has granted a license to Acadia Pharmaceuticals Inc. for the development and commercialization of trofinetide in North America, while retaining all rights outside North America. The firm is preparing to initiate Phase II trials of its second drug candidate, NNZ-2591, for each of PhelanMcDermid syndrome, Angelman syndrome and Pitt Hopkins syndrome. The company is also planning a Phase II trial in Prader-Willi syndrome.
See Also
What is Neuren Pharmaceuticals Ltd's Cash from Operating Activities?
Cash from Operating Activities
119.5m
AUD
Based on the financial report for Jun 30, 2024, Neuren Pharmaceuticals Ltd's Cash from Operating Activities amounts to 119.5m AUD.
What is Neuren Pharmaceuticals Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
117%
Over the last year, the Cash from Operating Activities growth was 120%.
You don't have any saved screeners yet
